RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Tranzyme Pharma, a late stage biopharmaceutical company engaged in the discovery and development of first-in-class small molecule therapeutics, announced today that the U.S. Patent and Trademark Office (USPTO) has issued three patents further enhancing Tranzyme’s intellectual property portfolio for its current and future drug candidates. They are:
